JHVEPhoto
Swiss drugmaker Sandoz (OTCQX:SDZNY) on Tuesday said that it has reached an agreement with U.S. drugmaker Amgen (NASDAQ:AMGN) resolving all patent disputes between the two companies relating to the Food and Drug Administration-approved Sandoz denosumab biosimilars.
The settlement clears the path to bring both denosumab biosimilars, Jubbonti and Wyost, to the U.S. market on May 31, 2025, or earlier under certain circumstances, Sandoz (OTCQX:SDZNY) said in a statement. Sandoz received FDA approval for the first denosumab biosimilars to treat skeletal-related events and osteoporosis on March 5, 2024.
Sandoz (OTCQX:SDZNY) further added that the terms of the agreement will not impact the company's previously disclosed 2024 guidance.